PHARMEDOX LIMITED
Executive Summary
PHARMEDOX LIMITED operates in the high-innovation biotechnology R&D sector but remains dormant with negligible financial activity since incorporation. Its current status places it outside typical industry operational benchmarks, reflecting a pre-startup phase. Future competitive positioning will depend on its ability to engage actively in R&D and secure funding amidst a dynamic and capital-intensive market environment.
View Full Analysis Report →Company Documents
| Date | Description |
|---|---|
| 29/09/2529 September 2025 New | Confirmation statement made on 2025-09-26 with no updates |
| 02/06/252 June 2025 | Accounts for a dormant company made up to 2024-09-30 |
| 30/09/2430 September 2024 | Annual accounts for year ending 30 Sep 2024 |
| 26/09/2426 September 2024 | Confirmation statement made on 2024-09-26 with no updates |
| 07/10/237 October 2023 | Accounts for a dormant company made up to 2023-09-30 |
| 07/10/237 October 2023 | Confirmation statement made on 2023-09-26 with no updates |
| 30/09/2330 September 2023 | Annual accounts for year ending 30 Sep 2023 |
| 27/06/2327 June 2023 | Accounts for a dormant company made up to 2022-09-30 |
| 10/10/2210 October 2022 | Confirmation statement made on 2022-09-26 with no updates |
| 30/09/2230 September 2022 | Annual accounts for year ending 30 Sep 2022 |
| 27/09/2127 September 2021 | Incorporation |
More Company Information
Follow Company
- Receive an alert email on changes to financial status
- Early indications of liquidity problems
- Warns when company reporting is overdue
- Free service, no spam emails Follow this company